Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Akebia Therapeutics, Inc. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are spread across distinct examiners, yet they are concentrated within 3 distinct art units. ROBINSON, MIKHAIL O'DONNEL is the busiest examiner, holding 1 pending office action.
The 5 pending office actions are handled by multiple individuals. With 3 distinct art units involved and exactly 1 matter for the busiest examiner, the portfolio shows a mix of technical concentration and examiner dispersion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991047 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | ROBINSON, MIKHAIL O'DONNEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991047 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | ROBINSON, MIKHAIL O'DONNEL | — |
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | — |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | — |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1641 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18991047 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | ROBINSON, MIKHAIL O'DONNEL | — | §102§103§112Other | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18742035 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOTTINGHAM, KYLE GREGORY | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18542100 | METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR | SZPERKA, MICHAEL EDWARD | 1641 | DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18500471 | Compositions and Methods for Treating Anemia | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18041490 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SHIM, DAVID M. | 1626 | §103 | Final Rejection | — | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAkebia Therapeutics, Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Mikhail O'Donnel Robinson has the most, with 1 of Akebia Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
